A simple screening test to help you understand your risk for hereditary breast and ovarian cancer.

Contact us to schedule an appointment

The BRCA genes (BRCA1 and BRCA2) are part of your body’s natural defense system. They help protect you from developing certain cancers.

If you have a BRCA gene that is not working properly (meaning, it carries a harmful), your lifetime risk to develop breast, ovarian and other cancers increases significantly.1

Lifetime Breast Cancer Risk

The average lifetime risk of breast cancer in Central and South America (by age 80) is up to 10%. A BRCA mutation can increase your risk up to 80%. 3

Lifetime Ovarian Cancer Risk

The average lifetime risk of ovarian cancer in Central and South America (by age 80) is up to 1%. A BRCA mutation can increase your risk up to 40%. 3

See references below

Why should you get screened?

The myBRCA test will

  • Help you understand your risk for developing hereditary breast and ovarian cancer
  • Improve your odds of early detection and prevention
  • Help identify other potential at risk family members

How it works

  1. Contact South Genetics to make an appointment
  2. Attend your appointment where your blood sample will be collected
  3. Your blood sample will be processed in VeritasGenetics’ CLIA approved laboratory
  4. The results will be delivered to you and your doctor

Technical Information

  • Next generation sequencing (NGS) on the Illumina® advanced platform
  • Clinically validated based on CDC, CAP, ACMG and CLSI guidelines
  • Analytical sensitivity and specificity of over 99.99%
  • Additional deletion/duplication assay included
  • Multi-ethnic validation (27.7% of validation samples were from non-white donors including persons of American, Hispanic, African-East Asian, and Middle Eastern ancestry)
  • Results interpreted by a physician trained in genetics with over 10 years of experience with NGS

For more technical information, download the following:

About VeritasGenetics

VeritasGenetics is a global pioneer in disease prevention through accessible genetic information. By removing the barriers to genetic screening, Veritas empowers individuals and doctors to make informed lifestyle decisions that can lead to disease prevention and longer and healthier lives. Veritas is founded by leaders in genomics from Harvard Medical School and operates globally from its o ces in the U.S., Europe and China.


+58 (212) 961-9611 / 9539 / 9456 / 9548 / 9451 +58 (0424) 254-3868 / +58 (0412) 273-8815 /

Centro Comercial Paseo El Hatillo, Torre de Oficinas, Piso 9, Ofic. 9-04 Urbanización La Lagunita / Caracas – Venezuela


  • Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 378(9801):1461-84, 2011.
  • Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:, accessed on 20/July/2016.
  • 1-National Cancer Institute. BRCA1 & BRCA2: Cancer Risk & Genetic Testing. 2015.NCI
  • 2-National Cancer Institute. BRCA1 & BRCA2: American Cancer Society. Breast cancer risk factors you cannot change. 2015.ACS
  • 3-Petrucelli N, Daly MB, Feldman GL. BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2013 Sep 26]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from:NCBI